Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

M. Hutchings, F. Morschhauser, G. Iacoboni,C. Carlo-Stella,F. C. Offner,A. Sureda,G. Salles, J. Martinez-Lopez, M. Crump, L. Lundberg,M. Dixon,A. Kwan, M. C. Wei, A-M E. Broeske,D. Carlile, C. O'Hear, M. J. Dickinson

ONCOLOGY RESEARCH AND TREATMENT(2020)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要